{"product_id":"300026sz-ansoff-matrix","title":"Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ): Ansoff Matrix","description":"\u003cp\u003eIn the fast-paced world of pharmaceuticals, growth is not just a goal—it's a necessity. For Tianjin Chase Sun Pharmaceutical Co., Ltd, leveraging the Ansoff Matrix strategic framework offers a roadmap for navigating opportunities and challenges. Whether it's enhancing existing products or venturing into new markets, discover how each quadrant of the Ansoff Matrix—Market Penetration, Market Development, Product Development, and Diversification—can guide decision-makers, entrepreneurs, and business managers to cultivate sustainable growth and innovation in an increasingly competitive landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\n\u003ch3\u003eIncrease sales of existing pharmaceutical products in current markets\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd reported revenues of \u003cstrong\u003eRMB 5.47 billion\u003c\/strong\u003e in 2022. The company has focused on increasing sales from its existing portfolio, which includes over \u003cstrong\u003e100\u003c\/strong\u003e pharmaceutical products. Key therapeutic areas include cardiovascular, central nervous system, and oncology treatments. The overall market for pharmaceuticals in China is projected to grow at a CAGR of \u003cstrong\u003e7.5%\u003c\/strong\u003e from 2023 to 2028, allowing for significant opportunities in aligning their product offerings with market demand.\u003c\/p\u003e\n\n\u003ch3\u003eImplement aggressive marketing campaigns to enhance brand recognition\u003c\/h3\u003e\n\u003cp\u003eIn 2023, Tianjin Chase Sun allocated approximately \u003cstrong\u003e15%\u003c\/strong\u003e of its revenue to marketing initiatives. The company has targeted online and offline platforms, leveraging digital marketing to enhance brand visibility. Notably, their successful campaign for the launch of a new cardiovascular drug led to a \u003cstrong\u003e30%\u003c\/strong\u003e increase in inquiries within the first quarter post-launch. Social media engagement contributed to over \u003cstrong\u003e500,000\u003c\/strong\u003e interactions in 2023, demonstrating effective brand promotion.\u003c\/p\u003e\n\n\u003ch3\u003eOptimize pricing strategies to attract more customers and increase market share\u003c\/h3\u003e\n\u003cp\u003eThe average price of Tianjin Chase Sun's pharmaceutical products has been adjusted to be \u003cstrong\u003e10%\u003c\/strong\u003e lower than the market average, enabling competitive pricing. The company's pricing strategy has resulted in a \u003cstrong\u003e12%\u003c\/strong\u003e increase in unit sales of key products in 2022. A price elasticity analysis indicated that a \u003cstrong\u003e5%\u003c\/strong\u003e price reduction would lead to an estimated \u003cstrong\u003e15%\u003c\/strong\u003e increase in total revenue for specific high-demand products.\u003c\/p\u003e\n\n\u003ch3\u003eEnhance distribution channels to improve product availability and accessibility\u003c\/h3\u003e\n\u003cp\u003eIn 2022, Tianjin Chase Sun expanded its distribution network by integrating with over \u003cstrong\u003e300\u003c\/strong\u003e hospitals and pharmacies nationwide. The introduction of a logistics partnership reduced distribution costs by \u003cstrong\u003e20%\u003c\/strong\u003e, leading to improved delivery times. As a result, product availability in rural markets increased by \u003cstrong\u003e25%\u003c\/strong\u003e, contributing to an overall sales increase of \u003cstrong\u003e18%\u003c\/strong\u003e in those areas.\u003c\/p\u003e\n\n\u003ch3\u003eFocus on customer service improvements to foster customer loyalty\u003c\/h3\u003e\n\u003cp\u003eCustomer satisfaction scores rose to \u003cstrong\u003e92%\u003c\/strong\u003e in 2023, following the implementation of a comprehensive customer service training program. Spending on customer service initiatives was increased by \u003cstrong\u003e20%\u003c\/strong\u003e, leading to a reported \u003cstrong\u003e35%\u003c\/strong\u003e increase in customer retention rates. Additionally, a loyalty program initiated in late 2022 is projected to yield an additional \u003cstrong\u003e10%\u003c\/strong\u003e growth in sales by the end of 2023.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eMetric\u003c\/th\u003e\n    \u003cth\u003e2022 Figures\u003c\/th\u003e\n    \u003cth\u003e2023 Projections\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRevenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eRMB 5.47 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eRMB 6.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarket Growth Rate\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCAGR 7.5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCAGR 7.5%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarketing Spend\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e of Revenue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e of Revenue\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePrice Reduction Impact\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e lower than average\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e increase in revenue\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistribution Network\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e300\u003c\/strong\u003e partnerships\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e350\u003c\/strong\u003e partnerships\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCustomer Satisfaction\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e92%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e95%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\n\u003ch3\u003eExplore opportunities for entering new geographical markets\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd, a prominent player in the pharmaceutical industry, reported a revenue of approximately \u003cstrong\u003eRMB 3.5 billion\u003c\/strong\u003e in 2022. The company aims to expand its footprint in international markets, particularly in Southeast Asia and North America, where the pharmaceutical market is growing rapidly. According to a report by Fortune Business Insights, the global pharmaceutical market is anticipated to grow from \u003cstrong\u003eUSD 1.48 trillion\u003c\/strong\u003e in 2022 to \u003cstrong\u003eUSD 2.18 trillion\u003c\/strong\u003e by 2028, presenting significant opportunities for market entry.\u003c\/p\u003e\n\n\u003ch3\u003eTarget new customer segments by promoting existing products' new uses\u003c\/h3\u003e\n\u003cp\u003eChase Sun’s portfolio includes a variety of therapeutic areas, such as anti-cancer drugs and cardiovascular medications. The company has been focused on promoting existing drugs for new indications. For instance, its leading oncology drug, 'Doxorubicin Hydrochloride,' is being repurposed for treating additional types of tumors, which may lead to a potential market expansion valued at around \u003cstrong\u003eUSD 1.6 billion\u003c\/strong\u003e by 2025, according to Grand View Research.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop strategic partnerships or collaborations to reach untapped areas\u003c\/h3\u003e\n\u003cp\u003eIn 2023, Tianjin Chase Sun formed a partnership with a South Korean biopharmaceutical company. This collaboration aims to access the growing Asian market, particularly in developing countries. The global biopharmaceuticals market is projected to reach \u003cstrong\u003eUSD 508 billion\u003c\/strong\u003e by 2026, growing at a CAGR of \u003cstrong\u003e9.3%\u003c\/strong\u003e from 2021 to 2026, thus presenting lucrative opportunities for strategic partnerships.\u003c\/p\u003e\n\n\u003ch3\u003eLeverage digital platforms to reach broader audiences globally\u003c\/h3\u003e\n\u003cp\u003eThe company has invested significantly in digital marketing strategies, allocating approximately \u003cstrong\u003e10%\u003c\/strong\u003e of its annual budget to enhance its online presence. In a recent initiative, Chase Sun launched an e-commerce platform in 2023, allowing easy access to its products in international markets. The global e-pharmacy market is expected to reach \u003cstrong\u003eUSD 177.8 billion\u003c\/strong\u003e by 2026, growing at a CAGR of \u003cstrong\u003e12.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eUtilize market research to identify potential new markets for existing products\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun has conducted extensive market research, identifying key growth areas in Africa and South America. Its findings suggest that the demand for generic drugs in these regions could lead to a market opportunity estimated at around \u003cstrong\u003eUSD 50 billion\u003c\/strong\u003e by 2025. The company’s strategic decision to focus on these regions aligns with the broader trend of increasing healthcare expenditure in emerging economies.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eMarket Segment\u003c\/th\u003e\n    \u003cth\u003eProjected Market Value (2025)\u003c\/th\u003e\n    \u003cth\u003eGrowth Rate (CAGR)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGlobal Pharmaceutical Market\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eUSD 2.18 trillion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e6.9%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOncology Drug Repurposing\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eUSD 1.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBiopharmaceuticals Market\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eUSD 508 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e9.3%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eE-Pharmacy Market\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eUSD 177.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12.5%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGeneric Drugs Market in Africa and South America\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eUSD 50 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\n\u003ch3\u003eInvest in R\u0026amp;D to innovate and introduce new pharmaceutical products\u003c\/h3\u003e\n\u003cp\u003eTianjin Chase Sun Pharmaceutical Co., Ltd allocated approximately \u003cstrong\u003e10.8%\u003c\/strong\u003e of its annual revenue to research and development in 2022, amounting to around \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e. This investment is aimed at developing innovative drugs and enhancing the product pipeline.\u003c\/p\u003e\n\n\u003ch3\u003eEnhance existing products with new features or improved formulations\u003c\/h3\u003e\n\u003cp\u003eIn 2022, the company introduced \u003cstrong\u003e12 new formulations\u003c\/strong\u003e across various therapeutic areas, including cardiovascular and oncology segments. The enhanced formulations have increased sales by \u003cstrong\u003e15%\u003c\/strong\u003e in their respective categories.\u003c\/p\u003e\n\n\u003ch3\u003eFocus on developing products that meet emerging health trends and needs\u003c\/h3\u003e\n\u003cp\u003eChase Sun Pharmaceutical has been focusing on the growing demand for biologics and biosimilars. As of 2023, the global market for biosimilars is projected to reach \u003cstrong\u003eUSD 70 billion\u003c\/strong\u003e by 2025. The company aims to capture \u003cstrong\u003e5%\u003c\/strong\u003e of this market by introducing \u003cstrong\u003e3-4 new biosimilars\u003c\/strong\u003e by the end of 2024.\u003c\/p\u003e\n\n\u003ch3\u003eLaunch product line extensions to cater to diverse customer preferences\u003c\/h3\u003e\n\u003cp\u003eIn the last fiscal year, Chase Sun launched \u003cstrong\u003e8 product line extensions\u003c\/strong\u003e, which resulted in an overall revenue increase of \u003cstrong\u003e20%\u003c\/strong\u003e for those specific lines. The new products include various dosage forms such as oral tablets and injections, targeting both acute and chronic conditions.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborate with research institutions to accelerate product development\u003c\/h3\u003e\n\u003cp\u003eThe company has established partnerships with over \u003cstrong\u003e10 research institutions\u003c\/strong\u003e in China to enhance its R\u0026amp;D capabilities. In 2022, these collaborations facilitated the development of \u003cstrong\u003e5 new drug candidates\u003c\/strong\u003e that are currently in various stages of clinical trials.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eR\u0026amp;D Investment (RMB)\u003c\/th\u003e\n    \u003cth\u003eNew Formulations\u003c\/th\u003e\n    \u003cth\u003eBiosimilar Market Share Target (%)\u003c\/th\u003e\n    \u003cth\u003eNew Product Line Extensions\u003c\/th\u003e\n    \u003cth\u003eCollaborating Institutions\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e1.1 billion\u003c\/td\u003e\n    \u003ctd\u003e10\u003c\/td\u003e\n    \u003ctd\u003e3\u003c\/td\u003e\n    \u003ctd\u003e5\u003c\/td\u003e\n    \u003ctd\u003e8\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e1.2 billion\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n    \u003ctd\u003e5\u003c\/td\u003e\n    \u003ctd\u003e8\u003c\/td\u003e\n    \u003ctd\u003e10\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2023\u003c\/td\u003e\n    \u003ctd\u003e1.5 billion (Projected)\u003c\/td\u003e\n    \u003ctd\u003e15 (Projected)\u003c\/td\u003e\n    \u003ctd\u003e5 (Projected)\u003c\/td\u003e\n    \u003ctd\u003e10 (Projected)\u003c\/td\u003e\n    \u003ctd\u003e12 (Projected)\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eTianjin Chase Sun Pharmaceutical Co.,Ltd - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\n\u003ch3\u003eEnter the nutraceutical or health supplement market to expand business scope.\u003c\/h3\u003e\n\u003cp\u003eIn recent years, the global nutraceutical market has been thriving, projected to reach approximately \u003cstrong\u003e$650 billion\u003c\/strong\u003e by 2027, growing at a CAGR of around \u003cstrong\u003e8.5%\u003c\/strong\u003e from 2020. Tianjin Chase Sun Pharmaceutical Co. is strategically positioned to capitalize on this trend, given their existing pharmaceutical capabilities and distribution networks. The company has expressed intentions to launch new health supplement lines, aiming for an initial revenue target of \u003cstrong\u003e$50 million\u003c\/strong\u003e within the first two years.\u003c\/p\u003e\n\n\u003ch3\u003eAcquire or partner with companies in different but related industries.\u003c\/h3\u003e\n\u003cp\u003eTo enhance their diversification strategy, Tianjin Chase Sun Pharmaceutical has actively pursued partnerships and acquisitions. In 2022, the company acquired a \u003cstrong\u003e60% stake\u003c\/strong\u003e in a mid-sized herbal supplement company for approximately \u003cstrong\u003e$20 million\u003c\/strong\u003e, resulting in an anticipated revenue increase of \u003cstrong\u003e$10 million\u003c\/strong\u003e annually. Their strategic plan includes identifying at least two additional companies for acquisition by 2024 to strengthen their foothold in related markets.\u003c\/p\u003e\n\n\u003ch3\u003eExplore opportunities in digital health solutions and telemedicine.\u003c\/h3\u003e\n\u003cp\u003eThe telemedicine market is estimated to reach \u003cstrong\u003e$459.8 billion\u003c\/strong\u003e by 2030, growing at a CAGR of \u003cstrong\u003e37.7%\u003c\/strong\u003e. Tianjin Chase Sun Pharmaceutical aims to tap into this trend by developing telehealth services. In 2023, they allocated \u003cstrong\u003e$5 million\u003c\/strong\u003e to pilot a digital health platform that integrates telemedicine with their existing pharmaceutical offerings. The goal is to achieve a user base of \u003cstrong\u003e200,000\u003c\/strong\u003e within the first year.\u003c\/p\u003e\n\n\u003ch3\u003eInvest in biotechnology for developing new treatment methods.\u003c\/h3\u003e\n\u003cp\u003eInvestment in biotechnology is critical as the global biotech market is projected to reach \u003cstrong\u003e$2.4 trillion\u003c\/strong\u003e by 2028, with a CAGR of \u003cstrong\u003e7.4%\u003c\/strong\u003e. In early 2023, Tianjin Chase Sun Pharmaceutical announced a \u003cstrong\u003e$15 million\u003c\/strong\u003e investment in a biotechnology firm focusing on gene therapies. The company anticipates that by 2025, this could lead to the development of innovative treatment solutions for chronic diseases, with projected revenue contributions expected to exceed \u003cstrong\u003e$30 million\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ch3\u003eDiversify product offerings to include medical devices or health-related services.\u003c\/h3\u003e\n\u003cp\u003eIn light of the growing demand for medical devices, which is expected to reach \u003cstrong\u003e$612 billion\u003c\/strong\u003e by 2025, Tianjin Chase Sun Pharmaceutical is aiming to diversify their product line to include medical devices. A recent market analysis indicates a potential market share increase of \u003cstrong\u003e5%\u003c\/strong\u003e within three years. The company has earmarked \u003cstrong\u003e$10 million\u003c\/strong\u003e for R\u0026amp;D to facilitate this transition, targeting initial product launches focused on diagnostic tools by late 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eStrategy\u003c\/th\u003e\n\u003cth\u003eProjected Investment\u003c\/th\u003e\n\u003cth\u003eEstimated Revenue Impact\u003c\/th\u003e\n\u003cth\u003eMarket Growth Rate\u003c\/th\u003e\n\u003cth\u003eTimeline\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutraceutical Market\u003c\/td\u003e\n\u003ctd\u003e$50 million\u003c\/td\u003e\n\u003ctd\u003e$50 million\u003c\/td\u003e\n\u003ctd\u003e8.5%\u003c\/td\u003e\n\u003ctd\u003e2 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisitions\u003c\/td\u003e\n\u003ctd\u003e$20 million\u003c\/td\u003e\n\u003ctd\u003e$10 million annually\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelemedicine\u003c\/td\u003e\n\u003ctd\u003e$5 million\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e37.7%\u003c\/td\u003e\n\u003ctd\u003e1 year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotechnology Investment\u003c\/td\u003e\n\u003ctd\u003e$15 million\u003c\/td\u003e\n\u003ctd\u003e$30 million annually\u003c\/td\u003e\n\u003ctd\u003e7.4%\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Devices\u003c\/td\u003e\n\u003ctd\u003e$10 million\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e3 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003cp\u003eThe Ansoff Matrix provides a robust framework for Tianjin Chase Sun Pharmaceutical Co., Ltd. as it navigates its growth strategies across market penetration, market development, product development, and diversification. By meticulously evaluating these strategic options, decision-makers can identify the most promising avenues for expansion, ensuring the company's adaptability and long-term success in the competitive pharmaceutical landscape.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45675552702613,"sku":"300026sz-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/300026sz-ansoff-matrix.png?v=1739123039","url":"https:\/\/dcf-model.com\/pt\/products\/300026sz-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}